NASDAQ: ILMN · Industrial Applications and Services · 6 alerts · CIK 1110803
Share price
$198.00Close, Nov 16
Market cap
$29.9B
Shares outstanding
151.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Illumina, Inc. filings on SEC EDGAR ↗
Illumina Director Keith A. Meister Sells $61.1M of Stock
Keith A. Meister, Director, sold 280,091 shares of Illumina, Inc. at $212.97 to $222.44 a share (average $218.12) in 21 transactions, worth $61.1M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 208,826 (-0.9%).
Illumina VP, CAO Scott D. Ericksen Sells $58.1K of Stock
Scott D. Ericksen, VP, CAO, sold 267 shares of Illumina, Inc. at $217.76 a share, worth $58.1K in total on Nov 10, 2026. Shares held after the trade: 14,029 (-1.9%).
Illumina Director Keith A. Meister Sells $66.6M of Stock
Keith A. Meister, Director, sold 281,433 shares of Illumina, Inc. at $225.12 to $241.42 a share (average $236.50) in 13 transactions, worth $66.6M in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 488,917 (-0.1%).
Illumina, Inc. reported total assets of $6.81 billion as of September 27, 2026, with a notable increase in goodwill and intangible assets following the acquisition of SomaLogic. The company reduced its current liabilities by paying down $499 million in term debt, while maintaining a cash position of $1.29 billion.
Illumina reported Q3 2026 revenue of $1.13 billion, up 4.2% year-over-year, driven by healthy clinical demand and robust NovaSeq X placements. Based on this momentum, the company raised its full-year 2026 revenue guidance to $4.64-$4.66 billion and non-GAAP EPS guidance to $5.40-$5.45.
“In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance.”
Jacob Thaysen, Chief Executive Officer of Illumina
“As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes.”
Jacob Thaysen, Chief Executive Officer of Illumina